98 results about "Blood concentration" patented technology

The invention discloses a method for detecting the concentration of cyclosporine in blood through fluorescence and electrochemical double signals, and belongs to the technical field of biochemical analysis and medical detection. Aiming at the technical problems of insufficient sensitivity and high false positive rate of traditional single-signal detection of blood concentration of cyclosporine, the method comprises the following steps: activating carboxyl microspheres by a coupling agent, fixing double-stranded DNA (deoxyribonucleic acid) formed by a cyclosporine aptamer and an initiator chain, inducing the initiator to release by using a cyclosporine sample, realizing strand displacement through an A2-PEI composite system, and detecting the blood concentration of cyclosporine by using an A < 2 >-PEI composite system. DNA modified cadmium telluride quantum dots are respectively adopted to detect fluorescence signals, eATRP electrochemical signal amplification is carried out to detect electrochemical signals, concentration values obtained by the two signals are verified, and an average value is taken as a result. The method can accurately capture low-concentration cyclosporine signals in blood, eliminates interference of a single method, is mainly used for accurately monitoring the blood concentration of cyclosporine, and provides a reliable detection means for medication safety and curative effect control of cyclosporine in clinical scenes such as organ transplantation.

To provide a method and device for predicting plasma concentration transition in combination of multiple drugs, by easily determining Ki, fm in vivo, and making them into a database, since, there has been dynamic prediction using a physiologic medicine speed theory (PBPK) model, as a prediction method of a drug interaction for medical products, however, prediction using an inhibition constant (Ki) of in vitro data and a contribution ratio (fm) of a metabolic enzyme, do not always match increase of clinical AUC.SOLUTION: There is provided a method for determining a parameter of a compartment model from a pharmacokinetic parameter of an interacted drug and interaction drug, then converting the compartment parameter into a PBPK model parameter, then determining by simulation using the PBPK model, a Ki value and fm being AUC increase ratios observed clinically. The acquired parameter is made into a database, and simulation of blood concentration transition of the interacted drug and interaction drug is performed.SELECTED DRAWING: Figure 1

The invention relates to pamoate drug sustained release microspheres and a preparation method thereof. According to the sustained-release microsphere preparation for injection prepared by the preparation method disclosed by the invention, the particle size distribution of the microspheres is relatively narrow, and the release time of active pharmaceutical ingredients can last for about three months to four months. Besides, the microsphere preparation prepared by the invention can maintain stable blood concentration in an animal body, has no large fluctuation of the blood concentration within 3-4 months, and better avoids the occurrence of toxic and side effects.

The invention relates to the technical field of medical instruments, and discloses a dynamic blood glucose monitoring system after kidney transplantation based on artificial intelligence, the system comprises a data acquisition and transmission module, an AI decision support module, a risk early warning and report generation module, a feedback and optimization module and a system integration module; an AI drug disturbance analysis module is arranged, when postoperation blood glucose is monitored in real time, an immunosuppressor-blood glucose dynamic response model is established, the causal relationship between the blood concentration of a specific drug and glucose metabolism is analyzed, and a drug correlation event label is labeled in real time; by means of the method, whether blood glucose fluctuation is triggered by immunosuppressor metabolism abnormality or not can be accurately recognized, it is avoided that drug-induced hyperglycemia is misjudged as an dietary event, the accuracy of treatment intervention decision making is guaranteed, and the rejection risk is reduced.

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

The present application relates to the technical field of federated learning, and particularly to a blood drug concentration anomaly analysis method based on federated learning, comprising the following steps: a center server generates and issues a proxy data set without privacy risk to a plurality of medical institution clients; and receiving local prediction logits generated and uploaded by the plurality of medical institution clients after predicting the proxy data set by using local heterogeneous models. In the present application, a dynamically evolving global prototype memory bank is combined for anomaly judgment, a normal prototype benchmark reflecting the latest global state is constructed by periodically fusing feature distributions extracted by each node at different time stages, so that anomaly detection no longer depends on static or isolated rules, but is based on a dynamically updated and collectively agreed dynamic standard, thereby improving the robustness and accuracy of anomaly judgment.

The invention discloses traditional Chinese medicine granules with an auxiliary blood pressure lowering effect and a preparation method thereof. The traditional Chinese medicine granules are prepared by mixing uncaria, scutellaria baicalensis, semen cassiae, the root of kudzu vine, selfheal, leonurus, gastrodia elata, microcrystalline cellulose and a ginseng essential oil slow-release agent and then carrying out granulation and freeze-drying processes. Wherein the ginseng essential oil sustained-release agent is prepared by adopting ginseng essential oil and Tween 80 to form a nano microemulsion, then wrapping the nano microemulsion in a chitosan and sodium linoleate compound coating solution and performing freeze drying, and the ginseng essential oil sustained-release agent prepared in the mode can effectively prevent the ginseng essential oil from being in contact with oxygen to cause an oxidation phenomenon; the core functions of the ginseng essential oil sustained-release preparation are to control the release rate of active ingredients, reduce the administration frequency, maintain more stable blood concentration or active ingredient level, prolong the retention time of the medicine in gastrointestinal tracts, further promote absorption and improve the bioavailability.

The present application relates to an extracorporeal blood treatment system (50) for treating a subject, the system comprising: an extracorporeal blood circuit (52); a dialysate fluid circuit (54); the extracorporeal blood circuit and the dialysate fluid circuit being separated by a membrane (56) of a filtration unit (58); at least one blood pump (60) for controlling the flow of blood through the blood circuit; at least one dialysate fluid pump (62) for controlling the flow of dialysate fluid through the dialysate fluid circuit (54); a system computing unit (64) operatively connected to the blood pump and to the dialysate fluid pump, the system computing unit having at least one input; wherein the system computing unit is adapted to receive a desired blood concentration of glutamine GLN b , to receive a desired blood concentration of glucose GLUCOSE b , and to receive a desired blood concentration of ketone bodies KETONE b ; the system computing unit being adapted to control the blood pump and the dialysate fluid pump such that an actual concentration value of glutamine GLN a is driven to approach GLN b , and an actual concentration value of glucose GLUCOSE a is driven to approach D b , and an actual concentration value of ketone bodies is driven to approach KETONE a . The present application relates to a treatment device for use in an extracorporeal blood treatment system, a method for treating cancer using the system, a controller for controlling the method and a dialysis liquid suitable for use in the method.

The invention relates to a riociguat prodrug as shown in a formula X or pharmaceutically acceptable salt thereof, a preparation method, an intermediate and a pharmaceutical composition thereof. The prodrug takes amino of riociguat as a modification site and is connected through an ester carrier, drug release is triggered by utilizing lung amidase, and lung targeted delivery is realized by adjusting a lipid-water partition coefficient. Pharmacokinetic studies show that the prodrug can significantly improve the drug concentration and total exposure of the lung, reduce the blood concentration of the whole body, and show excellent lung targeting characteristics. The invention also provides a pharmaceutical composition (preferably an inhalation preparation) containing the prodrug, and an application of the prodrug in preparation of drugs for preventing, treating, treating or relieving pulmonary arterial hypertension of patients. .

The invention belongs to the technical field of biological medicine, and particularly relates to a ganoderma lucidum polysaccharide sustained-release liver protection preparation and a preparation method thereof.The preparation comprises a pellet, the pellet comprises a pellet core, a medicine layer, an inner sustained-release layer and an outer mucous membrane attachment enteric-coated composite layer, and the pellet core is coated with the medicine layer, the inner sustained-release layer and the outer mucous membrane attachment enteric-coated composite layer in sequence; the medicine layer contains high-purity ganoderma lucidum polysaccharide; the inner slow-release layer is composed of ethyl cellulose, triethyl citrate and polyethylene glycol 4000; the outer mucous membrane attachment enteric composite layer is formed by compounding chitosan and a pH sensitive polymer, preferably, an in-situ network structure is formed through calcium ion crosslinking, and the outer mucous membrane attachment enteric composite layer has the enteric function and the mucous membrane attachment function. The invention aims to solve the problems that the existing ganoderan preparation is too fast in release, large in blood concentration fluctuation and short in action time. Through the synergistic effect of the structures, the ganoderma lucidum polysaccharide sustained-release liver protection preparation is stable in stomach, targeted in intestinal tract release and retained in mucous membranes, the sustained-release effect of 12 h or above is achieved, and the bioavailability and the liver protection curative effect are remarkably improved.

The present invention relates to a multiple controlled-release tablet composition of ruxolitinib or a pharmaceutically acceptable salt thereof, which is useful for treating Janus kinase-associated diseases such as myeloproliferative disorders, and a method for producing the same. More specifically, the present invention relates to a multiple controlled-release tablet composition and a method for producing the same, which exhibits a maximum drug blood concentration similar to that of commercially available immediate-release formulations, while controlling the drug release rate so as to efficiently maintain the drug at or above the effective blood concentration in the body, thereby enabling once-daily administration, unlike commercially available formulations that are administered twice daily.

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

The embodiment of the present application provides a medical detection device, comprising: a shell; a pressure measuring component, which is installed on the outer wall of the shell and is used for measuring the pressure of the environment outside the shell; and a concentration measuring component, which is installed on the outer wall of the shell and is used for measuring the concentration of a parameter to be measured in the environment outside the shell. The medical detection device in the embodiment of the present application can realize the detection of various parameters (including pH value, occult blood concentration, pepsin concentration and trypsin concentration) in the digestive tract, thereby improving the accuracy of the detection result of the medical detection device on the digestive tract. Meanwhile, the medical detection device can realize the measurement of the pressure in the digestive tract, thereby further improving the accuracy of the detection result. Moreover, the medical detection device can reduce the medical detection procedure and the number of devices required in the detection process, thereby saving the cost.

The invention relates to a preparation method and application of a suvortinib standard substance in human serum, and belongs to the field of medical examination. The standard substance is characterized by comprising the following three levels of suvaltinib solutions: a level 1: 10.00-50.00 [mu] g / L, a level 2: 10.00-50.00 [mu] g / L, and a level 3: 10.00-50.00 [mu] g / L; the level 2 is 450.00 to 750.00 [mu] g / L; the level is 3: 1200.00 to 2000.00 [mu] g / L; wherein the level 1 corresponds to the concentration range of the blood concentration trough of the suvortinib in the serum of a patient taking the medicine; the level 2 is an effective treatment blood concentration range; and the level 3 is the peak concentration range of the blood concentration. The standard substance can be used as a conventional detection limit and a reportable range of suvortinib in human serum. The standard substance has good uniformity, stability and interoperability, and can be applied to the fields of accuracy evaluation of blood concentration detection, detection result value traceability, performance evaluation of medical equipment, instrument calibration, research and development of medical equipment and the like.

The invention relates to the technical field of drug release adjustment, and particularly discloses a drug release adjustment method and system based on sweat pH value and temperature, and the method comprises the steps: S1, obtaining sweat pH value and skin surface temperature information of a region, and obtaining a signal A and a signal B respectively; s2, preprocessing to obtain a stabilized signal; s3, calculating an instantaneous drug release rate, and quantifying to obtain a current nano preparation release efficiency coefficient; S4, driving a microneedle channel to open and control to obtain a blood concentration; s5, sampling and detecting the released blood concentration to obtain a feedback concentration signal; s6, updating the release efficiency coefficient to obtain a nano preparation release efficiency coefficient of a new period; dual signals of sweat pH and skin surface temperature are synchronously collected, stable input is generated after pretreatment, subtle changes of body surface and in-vivo physiological states can be reflected in real time, and therefore richer and more reliable basis is provided for drug release decision, and drug delivery precision is effectively improved.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an arginine ibuprofen biphasic sustained release preparation and a preparation method thereof. Through a two-phase system of quick-release particles and slow-release particles, the problems that a traditional preparation takes effect slowly, is short in medicine effect and poor in taste are solved. Wherein the quick-release granules are prepared by mixing and granulating ibuprofen arginine, a filling agent, an adhesive and a natural flavoring agent, so that the effective blood concentration can be ensured to be reached within 15 minutes after the medicine is orally taken so as to quickly relieve pain, and the bad flavor of the medicine can be synchronously covered; the sustained-release granules are based on an ibuprofen arginine drug-loading core, the outer layer of the sustained-release granules is coated with a sustained-release film formed by a sustained-release agent and a plasticizer, and the effective blood concentration can be stably maintained for 6-8 hours, so that the medicine taking frequency is reduced, the sustained-release granules only need to be taken for 1-2 times every day, the medication compliance of a patient is greatly improved, and the sustained-release granules are suitable for clinical application. The traditional Chinese medicine composition is especially suitable for clinical scenes needing long-term or repeated analgesia such as chronic arthritis and postoperative pain, has excellent safety and practicability, and has a wide market application prospect.

According to the technical scheme, the constant volume device is characterized by comprising a base, two supporting plates are fixedly mounted on the top face of the base, a mounting plate is fixedly mounted between the supporting plates, and a constant volume bin is fixedly mounted in the mounting plate; the constant volume assembly is arranged above the base and used for carrying out constant volume on the blood medicine content in the constant volume bins, by arranging the constant volume assembly, the blood medicine content stored in the two constant volume bins can be limited, the blood medicine content stored in the two constant volume bins can be consistent, and during detection, the blood medicine content in the two constant volume bins can be accurately detected. The content of collected blood medicine added in blood medicine detection can be accurately controlled, the situation that residual air exists in the constant volume bin and influences the collection amount during blood medicine concentration detection is avoided, the phenomenon that detection results have errors due to the fact that the addition content of the detected blood medicine is different is effectively prevented, and the accuracy of the detection results is effectively improved.

The invention belongs to the technical field of biological detection and pharmaceutical analysis, and particularly relates to a method for determining dulcitine in blood plasma. The concentration of the dulcitine in the blood plasma is detected by adopting an ultra-high performance liquid chromatography-mass spectrometry method, a new guarantee means is provided for the medication safety of the tripterygium glycosides tablets, and meanwhile, a new method is provided for measuring the blood concentration of the dulcitine.

The invention provides a method for detecting the blood concentration of Shenfukang capsules. The method comprises the following steps: respectively preparing a first detection specimen containing a serum sample and a second detection specimen containing a urine sample; the method comprises the following steps: taking a first sample to be detected and a second sample to be detected, injecting a Supersil ODS 2 chromatographic column, taking 0.1% phosphoric acid aqueous solution-methanol as a mobile phase, respectively detecting the chromatographic peak of calycosin in the first sample to be detected and the chromatographic peak of rhein in the second sample to be detected, and calculating the concentration of calycosin and the concentration of rhein in the samples according to the chromatographic peaks; the chromatographic conditions of the first detection sample are that the detection wavelength is 260 nm, and gradient elution is carried out; the chromatographic conditions of the second detection sample are as follows: the detection wavelength is 254 nm, and isocratic elution is performed. The method has excellent repeatability and high sensitivity, the operation process is simple and easy to implement, the administration scheme can be accurately adjusted and an individualized administration strategy can be implemented in close combination with clinical manifestation and various inspection results of a patient, so that the safety and effectiveness of the medication process are ensured, and the method is suitable for clinical popularization and application. And a reliable medication guarantee is provided for the treatment of patients with chronic kidney diseases.

A brivaracetam pharmaceutical composition contains an active pharmaceutical ingredient, a matrix forming agent, and a swelling agent. It has a sustained release effect and has a more flat release curve compared with a common gel skeleton sustained-release preparation, and thus achieves the purposes of reducing the release rate of the medicament, controlling the in vivo effective dosage of the medicament, stabilizing the blood concentration, reducing toxic and side effects and reducing the times of daily administration.

The invention provides a preparation form and a preparation method of metformin. The preparation is composed of a tablet core and a controlled release film wrapping the tablet core, and the controlled release film is provided with at least one channel which allows the metformin or the pharmaceutically acceptable salt of the metformin to be released from the tablet core in a water phase environment. The design of the dosage form can control the release of the metformin or the pharmaceutically acceptable salt of the metformin to be less than 30% in 4 hours and less than 92% in 24 hours in a medium with the temperature of 37 DEG C and the pH value of 6.8. The design of the dosage form can control the plasma concentration of the metformin to reach the peak value at about 8-24 after the metformin or the pharmaceutically acceptable salt of the metformin is taken for a single time.

The invention provides an SERS (Surface Enhanced Raman Scattering) substrate and a detection method for the blood concentration of epirubicin, and belongs to the technical field of detection.The SERS substrate is prepared by the following steps: firstly, respectively preparing 40nm and 20nm gold nanoparticles through a sodium citrate reduction method, and constructing the SERS substrate on a silicon dioxide sheet through ABA sandwich dispensing; an epirubicin blood sample is pretreated through an acetonitrile precipitation method and then dropwise added to the substrate to be dried away from light, and the 1236 cm <-1 > characteristic peak intensity is detected through a 785 nm Raman spectrum. By establishing a quantitative curve of epirubicin concentration and peak intensity in serum, rapid quantitative detection of clinical samples is realized. The method is simple in sample treatment, high in detection sensitivity, good in repeatability, consistent with LC-MS / MS results, and suitable for bedside treatment drug monitoring.

The invention provides a gel emplastrum for treating oxaliplatin peripheral neurotoxicity and a preparation method, and relates to the field of traditional Chinese medicine, the gel emplastrum comprises a backing layer, an emplastrum layer and an anti-sticking layer; the paste layer is a gel layer formed by traditional Chinese medicine extract and a matrix for loading the traditional Chinese medicine extract; the traditional Chinese medicine extract is prepared from a traditional Chinese medicine composition; the traditional Chinese medicine composition comprises astragalus membranaceus, angelica sinensis, vinegar rhizoma sparganii, vinegar curcuma zedoary, cassia twig, achyranthes bidentata and pheretima in a mass ratio of 6: 3: 2: 2: 2: 4: 2. The matrix comprises a framework material, a cross-linking agent, a cross-linking regulator, a thickening agent, a humectant, a complexing agent, pure water, a preservative, a penetration enhancer, a thermal inductance regulator and a high-performance emulsifying thickening agent. The problems that in the prior art, a formula for promoting blood circulation to remove blood stasis is inconvenient to use in a soaking and washing main use mode, the patient compliance is poor, the speed of medicine entering the body of a patient is not easy to control, the blood concentration in the body of the patient is difficult to maintain stably, and the peripheral neurotoxicity treatment progress is difficult to control can be solved.

The invention relates to a crystal form of a bipyrimidine compound as well as a preparation method and application thereof. In particular, the present invention relates to a crystalline form I of 4 '-cyclopropyl-5, 6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl) bicyclo [2.2. 2] oct-1-yl) methyl)-[2, 5 '-bipyrimidinyl]-4-amine, a crystalline form II of 4'-cyclopropyl-5, 6 '-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl) bicyclo [2.2. 2] oct-1-yl) methyl)-[2 An X-ray powder diffraction pattern of the compound comprises characteristic peaks at diffraction angles (2 theta) of 6.378 + / -0.2 degrees, 9.521 + / -0.2 degrees, 15.721 + / -0.2 degrees, 16.379 + / -0.2 degrees, 16.981 + / -0.2 degrees, 17.560 + / -0.2 degrees, 19.080 + / -0.2 degrees and 22.200 + / -0.2 degrees. The crystal form I is high in stability, high in solubility, high in blood concentration, high in bioavailability and excellent in pharmacological action, so that the crystal form I is suitable for pharmaceutical preparations.

The invention provides a construction method of a precise medication model for mycophenolic acid drugs, a prediction device and electronic equipment. Belongs to the cross technical field of precision medicine and pharmacology. The construction method of the precise medication model for the mycophenolic acid drugs comprises the following steps: S1, acquiring clinical data of a patient; s2, collecting blood samples at different time points after the patient takes the medicine, and detecting the blood concentration of the mycophenolic acid medicine; s3, the non-atrioventricular model is used as a basic model, multiple linear regression analysis is carried out, a precise medication model for the mycophenolic acid drugs is established, and a mathematical model of the precise medication model for the mycophenolic acid drugs is shown as a formula (1). By the adoption of the accurate medication model for the mycophenolic acid drugs, the blood sampling frequency for monitoring the blood concentration of the mycophenolic acid drugs can be reduced, the workload of medical workers is reduced, the pain of patients is relieved, and the compliance of the patients is improved.

The invention relates to the field of heart failure risk assessment, in particular to an old-age heart failure early screening and hierarchical management system based on metabolic abnormality. According to the system, an initial heart failure performance value of a to-be-detected elderly patient is obtained according to a blood sodium concentration value of the to-be-detected elderly patient at each time point and the change of the blood sodium concentration value in a time sequence; according to the difference of the medication data information between the to-be-detected elderly patient and the to-be-selected elderly patient, the difference of the blood concentration values of the same medicine at each time point between the to-be-detected elderly patient and the to-be-selected elderly patient, and the time difference when the medicine is taken last time, determining the medication data information of the to-be-detected elderly patient; and screening a reference elderly patient of the to-be-detected elderly patient from all the to-be-selected elderly patients, and performing grading evaluation on the heart failure performance of the to-be-detected elderly patient according to the difference of the blood sodium concentration values of the to-be-detected elderly patient and the reference elderly patient at each time point and the initial heart failure performance value of the to-be-detected elderly patient. The accuracy of heart failure screening and grading evaluation of the elderly patients can be improved.

This invention relates to compounds of Formula I or salts thereof. The invention also provides the application of Formula I in the preparation of medicaments for treating JAK-related autoimmune diseases, inflammatory diseases, or cancers, which exhibit significant stability, maintain effective blood concentrations for a certain period, thereby prolonging the drug administration cycle, improving patient compliance, and reducing side effects caused by rapid drug release.

The invention provides an avibactam / ceftazidime blood concentration rapid joint detection test strip and a preparation method, system and application thereof. The system comprises an immunochromatography test strip and a time-resolved fluorescence detection system. The immunochromatography test strip comprises a sample pad, a combination pad, a nitrocellulose membrane detection area and an absorption pad; the sample pad is made of glass fibers treated by cane sugar or a surfactant; the combination pad is loaded with a time-resolved fluorescent microsphere coupled monoclonal antibody probe; an avibactam detection line T1, a ceftazidime detection line T2 and a quality control line C are arranged in the nitrocellulose membrane detection area according to the flowing direction; the absorption pad is made of cellulose materials. Compared with the prior art, rapid combined detection of the avibactam / ceftazidime blood concentration can be realized within 15 minutes, and the method has the advantages of high sensitivity, wide linear range, strong anti-interference capability and simplicity and convenience in operation, and can meet the bedside rapid detection requirement.

The invention provides a rivastigmine new-form salt compound and a preparation method of a rivastigmine new-form salt compound preparation. The rivastigmine new-form salt compound is prepared from the following rivastigmine salt and auxiliary materials in percentage by mass: 1.5%-3% of rivastigmine salt, 5%-10% of polysorbate 20, 1%-8% of polyethylene glycol-4000, 0.15%-1.5% of citric acid, 0.5%-1.0% of anhydrous disodium hydrogen phosphate, 0.1%-0.5% of sodium hydroxide and 80%-90% of water for injection. The invention also discloses a method for preparing a preparation by using the compound. The preparation process of the preparation disclosed by the invention is simple, is suitable for large-scale production of enterprises, and has great market development prospects. The preparation disclosed by the invention adopts a new administration mode, and the characteristics of the preparation are utilized, so that the medicine is slowly dissolved out subcutaneously; therefore, the purpose of reducing side effects of intestinal tracts is achieved. The preparation disclosed by the invention is stable in blood concentration and good in tolerance.

The present invention relates to a transdermal absorption preparation that can maintain a blood concentration sufficient to exert the efficacy of tandospirone, and also shows good storage stability against heat, humidity, and light. According to the present invention, a transdermal absorption preparation containing tandospirone or a pharmaceutically acceptable salt thereof, and levulinic acid, which is superior in the skin permeability of tandospirone or a pharmaceutically acceptable salt thereof in the preparation, and shows good preservation stability against heat and light can be provided.